Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, FL
State of incorporation
Nevada
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 231 % -60.5%
Debt-to-equity 48 % +38.7%
Return On Equity -46.3 %
Return On Assets -68.9 % -100%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.8M shares +9.77%
Common Stock, Shares, Outstanding 19.7M shares +9.81%
Entity Public Float 106M USD +2.91%
Common Stock, Value, Issued 20K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 19.3M shares +7.59%
Weighted Average Number of Shares Outstanding, Diluted 19.3M shares +7.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 131K USD -47.4%
Research and Development Expense 27.7M USD +64.6%
General and Administrative Expense 10.1M USD +8.43%
Operating Income (Loss) -37.8M USD -45.8%
Nonoperating Income (Expense) -1.6M USD -1720%
Net Income (Loss) Attributable to Parent -37.7M USD -41.9%
Earnings Per Share, Basic -2.06 USD/shares -40.1%
Earnings Per Share, Diluted -2.06 USD/shares -40.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.1M USD -35%
Accounts Receivable, after Allowance for Credit Loss, Current 3.14M USD
Assets, Current 35.5M USD -32.5%
Operating Lease, Right-of-Use Asset 363K USD -22.4%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 81K USD -37.7%
Assets 52.5M USD -24.8%
Liabilities, Current 15.1M USD +15.3%
Operating Lease, Liability, Noncurrent 322K USD -30.5%
Liabilities 15.4M USD -19.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -713K USD -0.14%
Retained Earnings (Accumulated Deficit) -142M USD -36.3%
Stockholders' Equity Attributable to Parent 36.3M USD -28.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 52.5M USD -24.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.48M USD -555%
Net Cash Provided by (Used in) Financing Activities -2.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 19.7M shares +9.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.85M USD -756%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.1M USD -35%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 19.6M USD +42.8%
Deferred Tax Assets, Gross 19.6M USD +43.1%
Operating Lease, Liability 452K USD -19.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.7M USD -41.9%
Lessee, Operating Lease, Liability, to be Paid 535K USD
Operating Lease, Liability, Current 130K USD +28.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 198K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 192K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 83K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.85M USD +25.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Additional Paid in Capital 179M USD +15%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 590K USD
Share-based Payment Arrangement, Expense 2.35M USD +26.1%
Interest Expense 250K USD -60.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%